Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2013

Open Access 01-12-2013 | Study protocol

RECODE: Design and baseline results of a cluster randomized trial on cost-effectiveness of integrated COPD management in primary care

Authors: Annemarije L Kruis, Melinde RS Boland, Catharina H Schoonvelde, Willem JJ Assendelft, Maureen PMH Rutten-van Mölken, Jacobijn Gussekloo, Apostolos Tsiachristas, Niels H Chavannes

Published in: BMC Pulmonary Medicine | Issue 1/2013

Login to get access

Abstract

Background

Favorable effects of formal pulmonary rehabilitation in selected moderate to severe COPD patients are well established. Few data are available on the effects and costs of integrated disease management (IDM) programs on quality of care and health status of COPD patients in primary care, representing a much larger group of COPD patients. Therefore, the RECODE trial assesses the long-term clinical and cost-effectiveness of IDM in primary care.

Methods/design

RECODE is a cluster randomized trial with two years of follow-up, during which 40 clusters of primary care teams (including 1086 COPD patients) are randomized to IDM or usual care. The intervention started with a 2-day multidisciplinary course in which healthcare providers are trained as a team in essential components of effective COPD IDM in primary care. During the course, the team redesigns the care process and defines responsibilities of different caregivers. They are trained in how to use feedback on process and outcome data to guide implement guideline-driven integrated healthcare. Practice-tailored feedback reports are provided at baseline, and at 6 and 12 months. The team learns the details of an ICT program that supports recording of process and outcome measures. Afterwards, the team designs a time-contingent individual practice plan, agreeing on steps to be taken in order to integrate a COPD IDM program into daily practice. After 6 and 12 months, there is a refresher course for all teams simultaneously to enable them to learn from each other’s experience. Health status of patients at 12 months is the primary outcome, measured by the Clinical COPD Questionnaire (CCQ). Secondary outcomes include effects on quality of care, disease-specific and generic health-related quality of life, COPD exacerbations, dyspnea, costs of healthcare utilization, and productivity loss.

Discussion

This article presents the protocol and baseline results of the RECODE trial. This study will allow to evaluate whether IDM implemented in primary care can positively influence quality of life and quality of care in mild to moderate COPD patients, thereby making the benefits of multidisciplinary rehabilitation applicable to a substantial part of the COPD population.

Trial registration

Netherlands Trial Register (NTR): NTR2268
Appendix
Available only for authorised users
Literature
1.
go back to reference GOLD: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2013 GOLD: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2013
2.
go back to reference Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW: Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008, 178: 332-338. 10.1164/rccm.200712-1869OC.CrossRefPubMed Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW: Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008, 178: 332-338. 10.1164/rccm.200712-1869OC.CrossRefPubMed
3.
go back to reference Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA: Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010, 11: 122-PubMedPubMedCentral Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA: Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010, 11: 122-PubMedPubMedCentral
4.
go back to reference Rabe KF, Wedzicha JA: Controversies in treatment of chronic obstructive pulmonary disease. Lancet. 2011, 378: 1038-1047. 10.1016/S0140-6736(11)61295-6.CrossRefPubMed Rabe KF, Wedzicha JA: Controversies in treatment of chronic obstructive pulmonary disease. Lancet. 2011, 378: 1038-1047. 10.1016/S0140-6736(11)61295-6.CrossRefPubMed
5.
go back to reference Nici L, Zuwallack R: An official American Thoracic Society workshop report: the Integrated Care of The COPD Patient. Proc Am Thorac Soc. 2012, 9: 9-18. 10.1513/pats.201201-014ST.CrossRefPubMed Nici L, Zuwallack R: An official American Thoracic Society workshop report: the Integrated Care of The COPD Patient. Proc Am Thorac Soc. 2012, 9: 9-18. 10.1513/pats.201201-014ST.CrossRefPubMed
6.
go back to reference Weingarten SR, Henning JM, Badamgarav E, Knight K, Hasselblad V, Gano A: Interventions used in disease management programmes for patients with chronic illness-which ones work? Meta-analysis of published reports. BMJ. 2002, 325: 925-10.1136/bmj.325.7370.925.CrossRefPubMedPubMedCentral Weingarten SR, Henning JM, Badamgarav E, Knight K, Hasselblad V, Gano A: Interventions used in disease management programmes for patients with chronic illness-which ones work? Meta-analysis of published reports. BMJ. 2002, 325: 925-10.1136/bmj.325.7370.925.CrossRefPubMedPubMedCentral
7.
go back to reference Lacasse Y, Goldstein R, Lasserson TJ, Martin S: Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2009, CD003793: Lacasse Y, Goldstein R, Lasserson TJ, Martin S: Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2009, CD003793:
8.
go back to reference Berry MJ, Rejeski WJ, Adair NE, Zaccaro D: Exercise rehabilitation and chronic obstructive pulmonary disease stage. Am J Respir Crit Care Med. 1999, 160: 1248-1253. 10.1164/ajrccm.160.4.9901014.CrossRefPubMed Berry MJ, Rejeski WJ, Adair NE, Zaccaro D: Exercise rehabilitation and chronic obstructive pulmonary disease stage. Am J Respir Crit Care Med. 1999, 160: 1248-1253. 10.1164/ajrccm.160.4.9901014.CrossRefPubMed
9.
go back to reference Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J: American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med. 2006, 173: 1390-1413. 10.1164/rccm.200508-1211ST.CrossRefPubMed Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J: American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med. 2006, 173: 1390-1413. 10.1164/rccm.200508-1211ST.CrossRefPubMed
10.
go back to reference Landry MD, Hamdan E, Al MS, Brooks D: The precarious balance between 'supply' and 'demand' for health care: the increasing global demand for rehabilitation service for individuals living with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2008, 3: 393-396.PubMedPubMedCentral Landry MD, Hamdan E, Al MS, Brooks D: The precarious balance between 'supply' and 'demand' for health care: the increasing global demand for rehabilitation service for individuals living with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2008, 3: 393-396.PubMedPubMedCentral
11.
go back to reference Yohannes AM, Connolly MJ: Pulmonary rehabilitation programmes in the UK: a national representative survey. Clin Rehabil. 2004, 18: 444-449. 10.1191/0269215504cr736oa.CrossRefPubMed Yohannes AM, Connolly MJ: Pulmonary rehabilitation programmes in the UK: a national representative survey. Clin Rehabil. 2004, 18: 444-449. 10.1191/0269215504cr736oa.CrossRefPubMed
12.
go back to reference Brooks D, Sottana R, Bell B, Hanna M, Laframboise L, Selvanayagarajah S: Characterization of pulmonary rehabilitation programs in Canada in 2005. Can Respir J. 2007, 14: 87-92.CrossRefPubMedPubMedCentral Brooks D, Sottana R, Bell B, Hanna M, Laframboise L, Selvanayagarajah S: Characterization of pulmonary rehabilitation programs in Canada in 2005. Can Respir J. 2007, 14: 87-92.CrossRefPubMedPubMedCentral
13.
go back to reference Tiep BL: Disease management of COPD with pulmonary rehabilitation. Chest. 1997, 112: 1630-1656. 10.1378/chest.112.6.1630.CrossRefPubMed Tiep BL: Disease management of COPD with pulmonary rehabilitation. Chest. 1997, 112: 1630-1656. 10.1378/chest.112.6.1630.CrossRefPubMed
14.
go back to reference Ries AL, Kaplan RM, Limberg TM, Prewitt LM: Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med. 1995, 122: 823-832. 10.7326/0003-4819-122-11-199506010-00003.CrossRefPubMed Ries AL, Kaplan RM, Limberg TM, Prewitt LM: Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med. 1995, 122: 823-832. 10.7326/0003-4819-122-11-199506010-00003.CrossRefPubMed
15.
go back to reference Griffiths TL, Burr ML, Campbell IA, Lewis-Jenkins V, Mullins J, Shiels K: Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial. Lancet. 2000, 355: 362-368. 10.1016/S0140-6736(99)07042-7.CrossRefPubMed Griffiths TL, Burr ML, Campbell IA, Lewis-Jenkins V, Mullins J, Shiels K: Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial. Lancet. 2000, 355: 362-368. 10.1016/S0140-6736(99)07042-7.CrossRefPubMed
16.
go back to reference Vale F, Reardon JZ, ZuWallack RL: The long-term benefits of outpatient pulmonary rehabilitation on exercise endurance and quality of life. Chest. 1993, 103: 42-45. 10.1378/chest.103.1.42.CrossRefPubMed Vale F, Reardon JZ, ZuWallack RL: The long-term benefits of outpatient pulmonary rehabilitation on exercise endurance and quality of life. Chest. 1993, 103: 42-45. 10.1378/chest.103.1.42.CrossRefPubMed
17.
18.
go back to reference Strijbos JH, Postma DS, van Altena R, Gimeno F, Koeter GH: A comparison between an outpatient hospital-based pulmonary rehabilitation program and a home-care pulmonary rehabilitation program in patients with COPD. A follow-up of 18 months. Chest. 1996, 109: 366-372. 10.1378/chest.109.2.366.CrossRefPubMed Strijbos JH, Postma DS, van Altena R, Gimeno F, Koeter GH: A comparison between an outpatient hospital-based pulmonary rehabilitation program and a home-care pulmonary rehabilitation program in patients with COPD. A follow-up of 18 months. Chest. 1996, 109: 366-372. 10.1378/chest.109.2.366.CrossRefPubMed
19.
go back to reference Kruis AL, Chavannes NH: Potential benefits of integrated COPD management in primary care. Monaldi Arch Chest Dis. 2010, 73: 130-134.PubMed Kruis AL, Chavannes NH: Potential benefits of integrated COPD management in primary care. Monaldi Arch Chest Dis. 2010, 73: 130-134.PubMed
20.
go back to reference Chavannes NH, Grijsen M, van den Akker M, Schepers H, Nijdam M, Tiep B: Integrated disease management improves one-year quality of life in primary care COPD patients: a controlled clinical trial. Prim Care Respir J. 2009, 18: 171-176.CrossRefPubMed Chavannes NH, Grijsen M, van den Akker M, Schepers H, Nijdam M, Tiep B: Integrated disease management improves one-year quality of life in primary care COPD patients: a controlled clinical trial. Prim Care Respir J. 2009, 18: 171-176.CrossRefPubMed
21.
go back to reference Chavannes N: Integrated Chronic Obstructive Pulmonary Disease Management in Primary Care. Dis Manage Health Outcomes. 2008, 16: 315-318. 10.2165/0115677-200816050-00007.CrossRef Chavannes N: Integrated Chronic Obstructive Pulmonary Disease Management in Primary Care. Dis Manage Health Outcomes. 2008, 16: 315-318. 10.2165/0115677-200816050-00007.CrossRef
22.
go back to reference Adams R, Chavannes N, Jones K, Ostergaard MS, Price D: Exacerbations of chronic obstructive pulmonary disease–a patients' perspective. Prim Care Respir J. 2006, 15: 102-109. 10.1016/j.pcrj.2006.01.003.CrossRefPubMed Adams R, Chavannes N, Jones K, Ostergaard MS, Price D: Exacerbations of chronic obstructive pulmonary disease–a patients' perspective. Prim Care Respir J. 2006, 15: 102-109. 10.1016/j.pcrj.2006.01.003.CrossRefPubMed
23.
go back to reference Lemmens KM, Nieboer AP, Huijsman R: A systematic review of integrated use of disease-management interventions in asthma and COPD. Respir Med. 2009, 103: 670-691. 10.1016/j.rmed.2008.11.017.CrossRefPubMed Lemmens KM, Nieboer AP, Huijsman R: A systematic review of integrated use of disease-management interventions in asthma and COPD. Respir Med. 2009, 103: 670-691. 10.1016/j.rmed.2008.11.017.CrossRefPubMed
24.
go back to reference Steuten LM, Lemmens KM, Nieboer AP, Vrijhoef HJ: Identifying potentially cost effective chronic care programs for people with COPD. Int J Chron Obstruct Pulmon Dis. 2009, 4: 87-100.PubMedPubMedCentral Steuten LM, Lemmens KM, Nieboer AP, Vrijhoef HJ: Identifying potentially cost effective chronic care programs for people with COPD. Int J Chron Obstruct Pulmon Dis. 2009, 4: 87-100.PubMedPubMedCentral
25.
go back to reference Kruis AL, Van AJ, Erkelens MR, Scheepers H, In V, Muris JW: Sustained effects of integrated COPD management on health status and exercise capacity in primary care patients. Int J Copd. 2010, 5: 407-413. Kruis AL, Van AJ, Erkelens MR, Scheepers H, In V, Muris JW: Sustained effects of integrated COPD management on health status and exercise capacity in primary care patients. Int J Copd. 2010, 5: 407-413.
26.
go back to reference Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A: Standardisation of spirometry. Eur Respir J. 2005, 26: 319-338. 10.1183/09031936.05.00034805.CrossRefPubMed Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A: Standardisation of spirometry. Eur Respir J. 2005, 26: 319-338. 10.1183/09031936.05.00034805.CrossRefPubMed
27.
go back to reference Smeele IJM, van Weel C, van Schayck CP, van der Molen T, Thoonen B, Schermer T: Dutch College of General Practitioners Guideline for COPD Diagnosis. Huisarts Wet. 2007, 50: 362-379. Smeele IJM, van Weel C, van Schayck CP, van der Molen T, Thoonen B, Schermer T: Dutch College of General Practitioners Guideline for COPD Diagnosis. Huisarts Wet. 2007, 50: 362-379.
28.
go back to reference Smelt AF, van der Weele GM, Blom JW, Gussekloo J, Assendelft WJ: How usual is usual care in pragmatic intervention studies in primary care? An overview of recent trials. Br J Gen Pract. 2010, 60: e305-e318.CrossRefPubMedPubMedCentral Smelt AF, van der Weele GM, Blom JW, Gussekloo J, Assendelft WJ: How usual is usual care in pragmatic intervention studies in primary care? An overview of recent trials. Br J Gen Pract. 2010, 60: e305-e318.CrossRefPubMedPubMedCentral
29.
go back to reference Kocks JW, Tuinenga MG, Uil SM, van den Berg JW, Stahl E, van der Molen T: Health status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaire. Respir Res. 2006, 7: 62-10.1186/1465-9921-7-62.CrossRefPubMedPubMedCentral Kocks JW, Tuinenga MG, Uil SM, van den Berg JW, Stahl E, van der Molen T: Health status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaire. Respir Res. 2006, 7: 62-10.1186/1465-9921-7-62.CrossRefPubMedPubMedCentral
30.
go back to reference van der Molen T, Willemse BW, Schokker S, ten Hacken NH, Postma DS, Juniper EF: Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes. 2003, 1: 13-10.1186/1477-7525-1-13.CrossRefPubMedPubMedCentral van der Molen T, Willemse BW, Schokker S, ten Hacken NH, Postma DS, Juniper EF: Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes. 2003, 1: 13-10.1186/1477-7525-1-13.CrossRefPubMedPubMedCentral
31.
go back to reference Jones PW: St. George's Respiratory Questionnaire: MCID. COPD. 2005, 2: 75-79. 10.1081/COPD-200050513.CrossRefPubMed Jones PW: St. George's Respiratory Questionnaire: MCID. COPD. 2005, 2: 75-79. 10.1081/COPD-200050513.CrossRefPubMed
32.
go back to reference Lamers LM, McDonnell J, Stalmeier PF, Krabbe PF, Busschbach JJ: The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. Health Econ. 2006, 15: 1121-1132. 10.1002/hec.1124.CrossRefPubMed Lamers LM, McDonnell J, Stalmeier PF, Krabbe PF, Busschbach JJ: The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. Health Econ. 2006, 15: 1121-1132. 10.1002/hec.1124.CrossRefPubMed
33.
go back to reference The Euro Qol Group: Euro Qol-a new facility for the measurement of health-related quality of life. 199–208. 1990, Amsterdam, the Netherlands: Health Policy The Euro Qol Group: Euro Qol-a new facility for the measurement of health-related quality of life. 199–208. 1990, Amsterdam, the Netherlands: Health Policy
34.
go back to reference Aaronson NK, Muller M, Cohen PD, Essink-Bot ML, Fekkes M, Sanderman R: Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. J Clin Epidemiol. 1998, 51: 1055-1068. 10.1016/S0895-4356(98)00097-3.CrossRefPubMed Aaronson NK, Muller M, Cohen PD, Essink-Bot ML, Fekkes M, Sanderman R: Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. J Clin Epidemiol. 1998, 51: 1055-1068. 10.1016/S0895-4356(98)00097-3.CrossRefPubMed
35.
go back to reference Schuurmans H, Steverink N, Frieswijk N, Buunk BP, Slaets JP, Lindenberg S: How to measure self-management abilities in older people by self-report. The development of the SMAS-30. Qual Life Res. 2005, 14: 2215-2228. 10.1007/s11136-005-8166-9.CrossRefPubMed Schuurmans H, Steverink N, Frieswijk N, Buunk BP, Slaets JP, Lindenberg S: How to measure self-management abilities in older people by self-report. The development of the SMAS-30. Qual Life Res. 2005, 14: 2215-2228. 10.1007/s11136-005-8166-9.CrossRefPubMed
36.
go back to reference Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA: Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999, 54: 581-586. 10.1136/thx.54.7.581.CrossRefPubMedPubMedCentral Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA: Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999, 54: 581-586. 10.1136/thx.54.7.581.CrossRefPubMedPubMedCentral
37.
go back to reference Glasgow RE, Wagner EH, Schaefer J, Mahoney LD, Reid RJ, Greene SM: Development and validation of the Patient Assessment of Chronic Illness Care (PACIC). Med Care. 2005, 43: 436-444. 10.1097/01.mlr.0000160375.47920.8c.CrossRefPubMed Glasgow RE, Wagner EH, Schaefer J, Mahoney LD, Reid RJ, Greene SM: Development and validation of the Patient Assessment of Chronic Illness Care (PACIC). Med Care. 2005, 43: 436-444. 10.1097/01.mlr.0000160375.47920.8c.CrossRefPubMed
38.
go back to reference Bonomi AE, Wagner EH, Glasgow RE, VonKorff M: Assessment of chronic illness care (ACIC): a practical tool to measure quality improvement. Health Serv Res. 2002, 37: 791-820. 10.1111/1475-6773.00049.CrossRefPubMedPubMedCentral Bonomi AE, Wagner EH, Glasgow RE, VonKorff M: Assessment of chronic illness care (ACIC): a practical tool to measure quality improvement. Health Serv Res. 2002, 37: 791-820. 10.1111/1475-6773.00049.CrossRefPubMedPubMedCentral
39.
go back to reference Devane D, Begley CM, Clarke M: How many do I need? Basic principles of sample size estimation. J Adv Nurs. 2004, 47: 297-302. 10.1111/j.1365-2648.2004.03093.x.CrossRefPubMed Devane D, Begley CM, Clarke M: How many do I need? Basic principles of sample size estimation. J Adv Nurs. 2004, 47: 297-302. 10.1111/j.1365-2648.2004.03093.x.CrossRefPubMed
40.
go back to reference Donner A, Birkett N, Buck C: Randomization by cluster. Sample size requirements and analysis. Am J Epidemiol. 1981, 114: 906-914.PubMed Donner A, Birkett N, Buck C: Randomization by cluster. Sample size requirements and analysis. Am J Epidemiol. 1981, 114: 906-914.PubMed
41.
go back to reference Smeeth L, Ng ES: Intraclass correlation coefficients for cluster randomized trials in primary care: data from the MRC Trial of the Assessment and Management of Older People in the Community. Contr Clin Trials. 2002, 23: 409-421. 10.1016/S0197-2456(02)00208-8.CrossRef Smeeth L, Ng ES: Intraclass correlation coefficients for cluster randomized trials in primary care: data from the MRC Trial of the Assessment and Management of Older People in the Community. Contr Clin Trials. 2002, 23: 409-421. 10.1016/S0197-2456(02)00208-8.CrossRef
42.
go back to reference Snijders TAB, Bosker RJ: Multilevel Analysis: An Introduction to Basic and Advanced Multilevel Modeling. 2011, London: Sage PublishersCrossRef Snijders TAB, Bosker RJ: Multilevel Analysis: An Introduction to Basic and Advanced Multilevel Modeling. 2011, London: Sage PublishersCrossRef
43.
go back to reference Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A: Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health. 2005, 8: 521-533. 10.1111/j.1524-4733.2005.00045.x.CrossRefPubMed Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A: Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health. 2005, 8: 521-533. 10.1111/j.1524-4733.2005.00045.x.CrossRefPubMed
44.
go back to reference College voor Zorgverzekeringen: Dutch guidelines for pharmacoeconomic research, evaluation and update. 2006, Diemen: Dutch Health Insurance Council College voor Zorgverzekeringen: Dutch guidelines for pharmacoeconomic research, evaluation and update. 2006, Diemen: Dutch Health Insurance Council
45.
go back to reference Koopmanschap MA, Rutten FF, Van Ineveld BM, Van RL: The friction cost method for measuring indirect costs of disease. J Health Econ. 1995, 14: 171-189. 10.1016/0167-6296(94)00044-5.CrossRefPubMed Koopmanschap MA, Rutten FF, Van Ineveld BM, Van RL: The friction cost method for measuring indirect costs of disease. J Health Econ. 1995, 14: 171-189. 10.1016/0167-6296(94)00044-5.CrossRefPubMed
46.
go back to reference Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ: Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008, 31: 416-469. 10.1183/09031936.00099306.CrossRefPubMed Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ: Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008, 31: 416-469. 10.1183/09031936.00099306.CrossRefPubMed
47.
go back to reference Al MJ: Cost-effectiveness acceptability curves revisited. Pharmacoeconomics. 2013, 31: 93-100. 10.1007/s40273-012-0011-8.CrossRefPubMed Al MJ: Cost-effectiveness acceptability curves revisited. Pharmacoeconomics. 2013, 31: 93-100. 10.1007/s40273-012-0011-8.CrossRefPubMed
48.
go back to reference Fenwick E, O'Brien BJ, Briggs A: Cost-effectiveness acceptability curves-facts, fallacies and frequently asked questions. Health Econ. 2004, 13: 405-415. 10.1002/hec.903.CrossRefPubMed Fenwick E, O'Brien BJ, Briggs A: Cost-effectiveness acceptability curves-facts, fallacies and frequently asked questions. Health Econ. 2004, 13: 405-415. 10.1002/hec.903.CrossRefPubMed
49.
go back to reference Fenwick E, Claxton K, Sculpher M: Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 2001, 10: 779-787. 10.1002/hec.635.CrossRefPubMed Fenwick E, Claxton K, Sculpher M: Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 2001, 10: 779-787. 10.1002/hec.635.CrossRefPubMed
50.
go back to reference Stinnett AA, Mullahy J: Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making. 1998, 18: S68-S80. 10.1177/0272989X9801800209.CrossRefPubMed Stinnett AA, Mullahy J: Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making. 1998, 18: S68-S80. 10.1177/0272989X9801800209.CrossRefPubMed
51.
go back to reference Boxall AM, Barclay L, Sayers A, Caplan GA: Managing chronic obstructive pulmonary disease in the community, A randomized controlled trial of home-based pulmonary rehabilitation for elderly housebound patients. J Cardiopulm Rehabil. 2005, 25: 378-385. 10.1097/00008483-200511000-00012.CrossRefPubMed Boxall AM, Barclay L, Sayers A, Caplan GA: Managing chronic obstructive pulmonary disease in the community, A randomized controlled trial of home-based pulmonary rehabilitation for elderly housebound patients. J Cardiopulm Rehabil. 2005, 25: 378-385. 10.1097/00008483-200511000-00012.CrossRefPubMed
52.
go back to reference Fernandez AM, Pascual J, Ferrando C, Arnal A, Vergara I, Sevila V: Home-based pulmonary rehabilitation in very severe COPD: is it safe and useful?. J Cardiopulm Rehabil Prev. 2009, 29: 325-331.CrossRefPubMed Fernandez AM, Pascual J, Ferrando C, Arnal A, Vergara I, Sevila V: Home-based pulmonary rehabilitation in very severe COPD: is it safe and useful?. J Cardiopulm Rehabil Prev. 2009, 29: 325-331.CrossRefPubMed
53.
go back to reference Gottlieb V, Lyngso AM, Nybo B, Frolich A, Backer V: Pulmonary rehabilitation for moderate COPD (GOLD 2)–does it have an effect?. COPD. 2011, 8: 380-386. 10.3109/15412555.2011.610393.CrossRefPubMed Gottlieb V, Lyngso AM, Nybo B, Frolich A, Backer V: Pulmonary rehabilitation for moderate COPD (GOLD 2)–does it have an effect?. COPD. 2011, 8: 380-386. 10.3109/15412555.2011.610393.CrossRefPubMed
54.
go back to reference Rea H, McAuley S, Stewart A, Lamont C, Roseman P, Didsbury P: A chronic disease management programme can reduce days in hospital for patients with chronic obstructive pulmonary disease. Intern Med J. 2004, 34: 608-614. 10.1111/j.1445-5994.2004.00672.x.CrossRefPubMed Rea H, McAuley S, Stewart A, Lamont C, Roseman P, Didsbury P: A chronic disease management programme can reduce days in hospital for patients with chronic obstructive pulmonary disease. Intern Med J. 2004, 34: 608-614. 10.1111/j.1445-5994.2004.00672.x.CrossRefPubMed
55.
go back to reference van Wetering CR, Hoogendoorn M, Mol SJ, Rutten-van Molken MP, Schols AM: Short- and long-term efficacy of a community-based COPD management programme in less advanced COPD: a randomised controlled trial. Thorax. 2010, 65: 7-13. 10.1136/thx.2009.118620.CrossRefPubMed van Wetering CR, Hoogendoorn M, Mol SJ, Rutten-van Molken MP, Schols AM: Short- and long-term efficacy of a community-based COPD management programme in less advanced COPD: a randomised controlled trial. Thorax. 2010, 65: 7-13. 10.1136/thx.2009.118620.CrossRefPubMed
56.
go back to reference Trappenburg JC, Koevoets L, de Weert-van Oene GH, Monninkhof EM, Bourbeau J, Troosters T: Action Plan to enhance self-management and early detection of exacerbations in COPD patients; a multicenter RCT. BMC Pulm Med. 2009, 9: 52-10.1186/1471-2466-9-52.CrossRefPubMedPubMedCentral Trappenburg JC, Koevoets L, de Weert-van Oene GH, Monninkhof EM, Bourbeau J, Troosters T: Action Plan to enhance self-management and early detection of exacerbations in COPD patients; a multicenter RCT. BMC Pulm Med. 2009, 9: 52-10.1186/1471-2466-9-52.CrossRefPubMedPubMedCentral
57.
go back to reference Herland K, Akselsen JP, Skjonsberg OH, Bjermer L: How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease?. Respir Med. 2005, 99: 11-19. 10.1016/j.rmed.2004.03.026.CrossRefPubMed Herland K, Akselsen JP, Skjonsberg OH, Bjermer L: How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease?. Respir Med. 2005, 99: 11-19. 10.1016/j.rmed.2004.03.026.CrossRefPubMed
Metadata
Title
RECODE: Design and baseline results of a cluster randomized trial on cost-effectiveness of integrated COPD management in primary care
Authors
Annemarije L Kruis
Melinde RS Boland
Catharina H Schoonvelde
Willem JJ Assendelft
Maureen PMH Rutten-van Mölken
Jacobijn Gussekloo
Apostolos Tsiachristas
Niels H Chavannes
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2013
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/1471-2466-13-17

Other articles of this Issue 1/2013

BMC Pulmonary Medicine 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine